Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2021-2040 of 3,900 trials

Acromegaly: Paltusotine Treatment Study

We are studying the long-term safety and effectiveness of paltusotine for people with acromegaly. This research aims to improve treatment options for managing this condition.

Acromegaly>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Carcinoid Syndrome: Paltusotine Treatment Study

We are evaluating the safety and how the body processes different doses of paltusotine in people with carcinoid syndrome. This study aims to ensure the treatment is safe and well-tolerated.

Carcinoid Syndrome3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Painful Venous Malformations: Apixaban Study

We are investigating whether apixaban can help reduce pain and improve quality of life for patients with painful venous malformations. The study also looks at safety and how the medication affects blood clotting.

Venous Malformation1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Diffuse Cutaneous Systemic Sclerosis: Ianalumab Study

We are testing a new medication, ianalumab, for people with diffuse cutaneous systemic sclerosis. The goal is to see if it improves symptoms and lung function compared to a placebo.

Systemic Scleroderma>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

Locally Advanced or Metastatic Synovial SarcomaLocally Advanced or Metastatic Desmoplastic Small Round Cell Tumor>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

OT-A201 for Blood Cancers and Solid Tumors

We are testing a new treatment called OT-A201 in patients with certain blood cancers and solid tumors. This study aims to understand its safety and effectiveness in humans.

Relapsed or Refractory Hematological Malignancies and Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Postoperative Pain Relief After Hip Surgery: Intrathecal Morphine Study

We are testing whether intrathecal morphine, with or without a specific nerve block, can improve pain relief after total hip arthroplasty. This study aims to find the best way to manage pain during recovery.

Total Hip Replacement Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Cardiovascular Risk Management: BIO-RISK-EVENT Study

We are testing a new approach to managing heart health in patients at high risk for heart events. The goal is to see if this intensified treatment is more effective than standard care.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Oxygen Therapy for Acute Pulmonary Embolism

We are investigating whether supplemental oxygen helps patients with intermediate-risk acute pulmonary embolism improve their health and reduce hospital stays. The study also looks at its effects on survival rates over time.

Acute Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyPulmonology

Knee Osteoarthritis: Intra-Articular Clodronate Study

We are investigating whether different doses of clodronate can help reduce knee pain and improve function in people with painful knee osteoarthritis. The study will also monitor safety and tolerability of the treatment.

Knee Osteoarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Dapagliflozin for Decompensated Liver Cirrhosis

We are studying whether dapagliflozin is safe and effective for patients with decompensated liver cirrhosis compared to standard treatments. The trial also looks at how it may affect quality of life and various health markers.

Decompensated Liver Cirrhosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Prostate Cancer: Neoadjuvant Xaluritamig Study

We are testing a new treatment called Xaluritamig for men with newly diagnosed localized intermediate or high-risk prostate cancer. The goal is to see how well it works before surgery.

Localized Intermediate or High-Risk Prostate Cancer>2 yearsSafety phase (I)Oncology

Non-Hodgkin Lymphoma: New CAR T-Cell Therapy Study

We are comparing a new point-of-care CAR T-cell treatment to a standard commercial option for patients with relapsed or refractory Non-Hodgkin Lymphoma. The goal is to see if the new therapy can improve survival and safety outcomes.

Relapsed/Refractory Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: WVE-006 Treatment

We are testing a new treatment called WVE-006 for people with Pi*ZZ Alpha-1 Antitrypsin Deficiency. The study aims to evaluate its safety and how the body responds to it.

Alpha-1 Antitrypsin Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyGastroenterologyHepatologyInternal MedicinePulmonology

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

HER2-Positive Glioblastoma: NK-92/5.28.z Cells and Ezabenlimab

We are investigating a new treatment combining NK-92/5.28.z cells with Ezabenlimab for patients with recurrent HER2-positive glioblastoma. This study aims to see if this combination can improve treatment outcomes.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Idiopathic Bile Acid Diarrhea: Colesevelam Hydrochloride Tablet

We are studying a new tablet for patients with idiopathic bile acid diarrhea to see if it improves stool consistency compared to a placebo. The trial will also evaluate the safety and tolerability of this treatment.

Bile Acid Diarrhoea≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Short Bowel Syndrome: Crofelemer Study

We are testing crofelemer to see if it helps adults with Short Bowel Syndrome and Intestinal Failure manage their symptoms better. The study will assess its safety and effectiveness compared to a placebo.

Short Bowel Syndrome and Intestinal Failure6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Pneumonia in Preschool Children: Amoxicillin Study

We are investigating whether amoxicillin helps preschool children with pneumonia compared to a placebo. The study also looks at how the antibiotic affects airway bacteria and other related factors.

Community Acquired Pneumonia>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteInfectious DiseasesPulmonology

Atezolizumab for Muscle-Invasive Bladder Cancer

We are studying whether atezolizumab can help patients with muscle-invasive bladder cancer who cannot have surgery after chemo-radiotherapy. The trial looks at how well it works and its impact on patients' quality of life.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology